In patients with angina despite non-obstructive coronary arteries (ANOCA), coronary vasomotion disorders (CVD) are a common cause for their symptoms. Due to the heterogeneous clinical presentation resulting from a broad spectrum of endotypes, symptom management still remains a major challenge. We aimed to demonstrate that endotype-based pharmacotherapy can improve angina severity and quality of life (QoL) outcomes in these patients.